To determine the necessity for the heightened level of monitoring for cataract development in patients taking quetiapine (Seroquel, AstraZeneca Pharmaceutical s, Wilmington, Delaware) dictated by the Physicians’Desk ...To determine the necessity for the heightened level of monitoring for cataract development in patients taking quetiapine (Seroquel, AstraZeneca Pharmaceutical s, Wilmington, Delaware) dictated by the Physicians’Desk Reference. Also, to ex plore the possibility of cataractogenesis because of quetiapine therapy. Observa tional case series. Data were garnered from a series of 80 case reports collecte d at the National Registry of Drug Induced Ocular Side Effects (Portland, Orego n). The World Health Organization (WHO) causality assessment guidelines were use d to assess the relationship between quetiapine and cataractogenesis. There were 34 reports of cataracts associated with quetiapine therapy. Average age was 44 years with 23 females and 11 males studied. Average duration of therapy was 29.3 weeks on standard doses. Cataractogenesis secondary to quetiapine is unlikely b y WHO guidelines. This probably makes it unnecessary to require biannual ophthal mic examinations as routine eye examinations are sufficient to screen for this c ondition.展开更多
文摘To determine the necessity for the heightened level of monitoring for cataract development in patients taking quetiapine (Seroquel, AstraZeneca Pharmaceutical s, Wilmington, Delaware) dictated by the Physicians’Desk Reference. Also, to ex plore the possibility of cataractogenesis because of quetiapine therapy. Observa tional case series. Data were garnered from a series of 80 case reports collecte d at the National Registry of Drug Induced Ocular Side Effects (Portland, Orego n). The World Health Organization (WHO) causality assessment guidelines were use d to assess the relationship between quetiapine and cataractogenesis. There were 34 reports of cataracts associated with quetiapine therapy. Average age was 44 years with 23 females and 11 males studied. Average duration of therapy was 29.3 weeks on standard doses. Cataractogenesis secondary to quetiapine is unlikely b y WHO guidelines. This probably makes it unnecessary to require biannual ophthal mic examinations as routine eye examinations are sufficient to screen for this c ondition.
